Evidence from murine tumor models indicates that the depletion of CD103+ cells results in reduced effectiveness of checkpoint inhibitor treatments, highlighting the importance of these TRM cells in the response to cancer immunotherapy (54). This evidence concerns the gene ITGAE and neoplasm.